Summary:
A Phase 3b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation
Qualified Participants Must:
• Men and women 18 through 65 years of age (inclusive) with a diagnosis of schizophrenia, who are experiencing an acute exacerbation or relapse of symptoms requiring hospitalization with onset less than 2 months prior to screening may be eligible for this study
Qualified Participants May Receive:
Compensation for time and gas